Liquid chromatography–tandem mass spectrometry (LC–MS/MS) reveals distinct sphingolipid patterns in anorexia and obesity.
|Articles|August 1, 2013
- LCGC North America-08-01-2013
- Volume 31
- Issue 8
Vol 31 No 8 LCGC North America August 2013 Regular Issue PDF
Click the title above to open the LCGC North America August 2013 regular issue, Vol 31 No 8, in an interactive PDF format.
Advertisement
Articles in this issue
over 13 years ago
Gradient Elution, Part VI: Ghost Peaksover 13 years ago
Troubleshooting GC Selectivity, Resolution, and Baseline Issuesover 13 years ago
How Reversed-Phase Liquid Chromatography Worksover 13 years ago
Peaks of Interestover 13 years ago
A Three-Pronged Template Approach for Rapid HPLC Method Developmentover 13 years ago
Market Profile: Continuous Flow Analysis and Discrete AnalyzersAdvertisement
Related to this article
Leon Niezen and Gert Desmet discuss uncertainty-driven LC method development, peak overlap, and moving from in silico to real data.
Leon Niezen and Gert Desmet describe how predictive uncertainty can make automated LC method development more reliable.
Liquid chromatography–mass spectrometry (LC–MS) serum profiling ties lysine compounds to lupus kidney disease.
Liquid chromatography-mass spectrometry (LC–MS) growth lifts Waters Q3; MOBILion ion mobility buy expands proteomics.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) measures galactose-1-phosphate in dried blood spots to monitor galactosemia.
Sam Whitmarsh explores how retention-time models handle interlaboratory data, novel chemotypes, unusual phases and ionisable compounds, and what labs need to do to build useful in-house models.
Advertisement
Advertisement
Trending on LCGC International
1
AI/ML Now: Toxicity Prediction for Unknown LC–HRMS Features Using Machine Learning
2
LCGC Blog: Building a Career Series That Goes Beyond the Surface
3
Industry Roundup: Waters Posts Strong Third Quarter as LC–MS and Chromatography Consumables Drive Growth, Acquires Ion Mobility Pioneer MOBILion
4
From 9000 Clues to a Clinical Test: Mass Spectrometry-Driven Lipidomics for Early Cancer Detection
5